-+ 0.00%
-+ 0.00%
-+ 0.00%

SHANGHAI HENLIUS BIOTECH - ASTRIDE TRIAL SHOWS FAVORABLE MEDIAN OVERALL SURVIVAL FOR SERPLULIMAB VS ATEZOLIZUMAB

Reuters·10/27/2026 08:25:10